Lu177PSMATherapyQualityChecker
Lu-177 PSMA Therapy Quality Checker
Lu-177 PSMA Therapy Quality Checker — Quality control of Lu-177 PSMA for prostate cancer therapy
ℹ️ Utility checks critical parameters of Lu-177 PSMA:
- Radiochemical purity (≥95%)
- Free lutetium (≤2%)
- Precursor residue (<0.1%)
- Specific activity (≥20 GBq/mg)
- Lu-177m impurity (<0.01%) — CRITICAL!
⚠️ CRITICAL: Lu-177m (T½=160 days) creates long-term radiation burden!
Lu-177 PSMA is used for metastatic prostate cancer therapy.
High specific activity is necessary for effective PSMA binding.
Usage
Lu177PSMATherapyQualityChecker.exe → demo mode (console output)
Lu177PSMATherapyQualityChecker.exe input.csv output.json → evaluate your data
Input format
BatchNumber,RadiochemicalPurityPercent,FreeLutetiumPercent,PrecursorPercent,SpecificActivityGBq_per_mg,pH,ResidualSolventsPPM,EndotoxinsEU_per_mL,SterilityTest,ActivityGBq,RadionuclidicPurityPercent,Lu177mImpurityPercent
Example
LU177-PSMA-THER-2026-001,99.2,0.4,0.02,50.0,5.0,80.0,5.0,0,7.4,99.99,0.0003
— WHY IS THIS NEEDED?
Lu-177 PSMA (e.g., based on PSMA-617 or I&T ligand) is breakthrough in metastatic castration-resistant prostate cancer therapy.
- Binds to prostate-specific membrane antigen (PSMA).
- Lu-177 emits beta particles for therapy and gamma quanta for imaging.
- Half-life 6.65 days.
- Requires high radiochemical purity and specific activity.
⚠️ CRITICAL:
- Radiochemical purity ≥95% — guarantee of dose delivery to tumor.
- Free lutetium ≤2% — free ions accumulate in bones and liver.
- Precursor residue <0.1% — unreacted ligand competes for PSMA receptors.
- Specific activity ≥20 GBq/mg — necessary for high contrast and efficacy.
- Lu-177m impurity <0.01% — Lu-177m is long-lived and creates unnecessary radiation burden.
- pH 4.5-6.5 — optimal media for Lu-PSMA complex stability.
- Residual solvents must be minimal (<500 ppm).
- Endotoxins <175 EU/mL — standard for parenteral drugs.
- Sterility — MANDATORY.
Key features
- Strict control of Lu-177m impurity characteristic of reactor production.
- Assessment of residual precursor, critical for therapy efficacy.
- Specific activity check for effective targeting.
- Compliance with GMP and Pharmacopoeia requirements for Lu-177 radiopharmaceuticals.
- Comprehensive safety check (endotoxins, sterility, pH, solvents).
Critical parameters
- Radiochemical purity: ≥95.0%
- Free lutetium: ≤2.0%
- Precursor residue: <0.1%
- Specific activity: ≥20.0 GBq/mg
- Radionuclidic purity: ≥99.9%
- Lu-177m impurity: <0.01%
- Residual solvents: <500 ppm
- pH: 4.5–6.5
- Endotoxins: <175 EU/mL
- Sterility: no growth
💡 Usage tips:
1. Radiochemical purity determined by TLC or HPLC.
2. Lu-177m impurity controlled by gamma spectrometry.
3. Synthesis usually performed on automatic modules or manually using kits.
4. Drug is stable for several days due to strong DOTA/HBED-CC complex.
5. Lu-177 emits gamma quanta 208 and 113 keV, allowing post-therapeutic imaging.
⚠️ Note: Lu-177 PSMA represents successful theranostics example (therapy + diagnostics). Quality control here is critical as error in dosing or purity can lead either to treatment inefficacy or serious toxicity to salivary glands, kidneys and bone marrow.
input.csv
BatchNumber,RadiochemicalPurityPercent,FreeLutetiumPercent,PrecursorPercent,SpecificActivityGBq_per_mg,pH,ResidualSolventsPPM,EndotoxinsEU_per_mL,SterilityTest,ActivityGBq,RadionuclidicPurityPercent,Lu177mImpurityPercent LU177-PSMA-THER-2026-001,99.2,0.4,0.02,50.0,5.0,80.0,5.0,0,7.4,99.99,0.0003 LU177-PSMA-THER-2026-002,97.5,1.8,0.08,45.0,4.8,150.0,15.0,0,7.0,99.95,0.0008 LU177-PSMA-THER-2026-003,92.0,4.5,0.2,30.0,6.2,550.0,40.0,1,6.0,99.60,0.0020
URS & FS — user requirements and functional specification
URS — User Requirements Specification
- The utility shall accept
input.csvwith these mandatory columns:BatchNumber,RadiochemicalPurityPercent,FreeLutetiumPercent,PrecursorPercent,SpecificActivityGBq_per_mg,pH,ResidualSolventsPPM,EndotoxinsEU_per_mL,SterilityTest,ActivityGBq,RadionuclidicPurityPercent,Lu177mImpurityPercent. - Each row shall be processed as a separate batch or record identified by
BatchNumber. - Before evaluation, the utility shall validate the CSV structure, mandatory values, numeric fields and allowed text values.
- Rules and limits shall be applied to every parameter in the input row.
- Critical violations identified in the supplied description shall set the record result to FAIL.
- Each row shall receive an overall PASS, WARNING or FAIL status with the triggered rules.
- An invalid row shall not receive PASS.
output.jsonshall contain source values, applied limits, individual check results and errors.- The same input and the same rule profile shall produce the same result.
FS — Functional Specification
- Run
Lu177PSMATherapyQualityChecker.exein demonstration mode or withinput.csv output.jsonarguments. - Read UTF-8 CSV and verify the exact set of mandatory columns.
- Convert row values to numeric and text types.
- Apply the rules defined in the approved version or configuration profile.
- Generate individual check results and derive the overall status from the most severe violation.
- Write machine-readable
output.json. - Structural and type errors shall be reported explicitly and shall not be masked by a successful status.
Complete input.csv example
BatchNumber,RadiochemicalPurityPercent,FreeLutetiumPercent,PrecursorPercent,SpecificActivityGBq_per_mg,pH,ResidualSolventsPPM,EndotoxinsEU_per_mL,SterilityTest,ActivityGBq,RadionuclidicPurityPercent,Lu177mImpurityPercent LU177-PSMA-THER-2026-001,99.2,0.4,0.02,50.0,5.0,80.0,5.0,0,7.4,99.99,0.0003 LU177-PSMA-THER-2026-002,97.5,1.8,0.08,45.0,4.8,150.0,15.0,0,7.0,99.95,0.0008 LU177-PSMA-THER-2026-003,92.0,4.5,0.2,30.0,6.2,550.0,40.0,1,6.0,99.60,0.0020
Purpose of the supplied test rows
- The first row contains values consistent with the criteria stated in the supplied description.
- The second row contains values closer to the limits or moderate deviations.
- The third row contains clear deviations for negative-result testing.
Minimum output.json structure
{
"utility": "Lu177PSMATherapyQualityChecker",
"source": "input.csv",
"results": [
{
"batchNumber": "BATCH-001",
"status": "PASS",
"checks": [
{
"parameter": "ParameterName",
"value": 0,
"limit": "configured rule",
"status": "PASS"
}
],
"errors": []
}
]
}
Minimum OQ scenarios
- Process the complete supplied
input.csv. - Remove a mandatory column and confirm a contract error.
- Provide text instead of a numeric value and confirm a type error.
- Test values directly on the configured limits.
- Repeat the run with the same input and confirm an identical result.
Before operational use
- Reconcile rules and limits with the approved specification, methods and SOP.
- Fix the executable version and rule-profile version.
- Retain the source CSV together with the generated JSON.
Included in packages
PetRad QC Suite
A specialised utility package for radiopharmaceutical quality control: PET, SPECT, therapeutic radionuclides, generators and decay calculations.
OpenPetRad3: expanded PET/SPECT and radiopharmaceutical QC package
A curated suite for PET/SPECT radiopharmaceuticals, generator and cyclotron radionuclides, labelled compounds, radiochemical purity, breakthrough, sterility and endotoxin control.
OpenRadioligand & Theranostics Expansion QC Suite
Radioligand & Theranostics Expansion QC Suite: FUZKK utility package for CSV→JSON QC checks with EU-first limit priority.
OpenRadiopharmaceutical Diagnostics and Therapy QC Suite
36 utilities for clinically oriented radiopharmaceutical and workflow quality control: PET/SPECT tracers, the Tc-99m renal workflow, PRRT, PSMA therapy, targeted alpha therapy, radioembolization, bone-pain palliation, immuno-PET and generator-based radionuclide control.
OpenRPH isotope family: beta-emitting therapy
Lu-177, Y-90, Ho-166, Re-188, Sm-153, Sr-89, P-32, Cu-67 and Tb-161.
OpenRPH organ/system: bone and musculoskeletal
Bone scintigraphy, MDP/PYP, marrow, bone-pain palliation, skeletal metastases and radiosynovectomy.
OpenRPH organ/system: hepatobiliary and GI
HIDA, mebrofenin, gallbladder, gastric emptying, GI transit, bleeding and liver/spleen imaging.
OpenRPH organ/system: oncology and theranostics
Tumour imaging, PSMA/FAPI/receptor tracers, immuno-PET, targeted radionuclide therapy and radioembolization.
OpenRPH organ/system: renal and urinary
Renography, GFR/ERPF, renal uptake, DMSA/MAG3/DTPA and bladder-related workflows.
OpenRPH use case: radionuclide therapy and theranostics
Lu-177, Ac-225, Ra-223, Y-90, Ho-166, Sm-153, Sr-89, Re-188, Tb-161, I-131 and other therapeutic radiopharmaceuticals: activity, purity, free metal, daughters and toxicological constraints.
OpenRPH workflow: generators and isotope purity
Generator eluate, breakthrough, radionuclidic purity, isotope mix and starting radionuclides.
OpenRPH workflow: imaging QC and quantitative interpretation
Acquisition, uptake, clearance, perfusion, transit, ejection fraction, segmentation and quantitative imaging.
OpenRPH workflow: product release QC
Assay, purity, sterility, endotoxins, pH, impurities, appearance and batch-release checks.
OpenRPH workflow: stability, storage, decay and waste
Kinetic stability, shelf life, decay correction, expiry, storage, trend and radioactive waste.
OpenRPH workflow: synthesis, labelling and kit reconstitution
Radiolabelling, synthesis, chelation, reducing agent, pH/stoichiometry and kit preparation.
OpenRPH: combined radiopharmaceutical QC package
RPH combines PetRad, PetRad2 and PetRad3 into one umbrella package for PET/SPECT, therapeutic radionuclides, generators, labelled compounds, decay calculations, sterility, endotoxins and radiochemical/radionuclidic purity.
Open